-
1
-
-
33846995628
-
Economics of new oncology drug development
-
DiMasi J.A., Grabowski H.G. Economics of new oncology drug development. J. Clin. Oncol. (2007) 25 209-216.
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 209-216
-
-
Dimasi, J.A.1
Grabowski, H.G.2
-
2
-
-
4344645978
-
Can the pharmaceutical industry reduce attrition rates?
-
Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. (2004) 3 711-715.
-
(2004)
Nat. Rev. Drug Discov.
, vol.3
, pp. 711-715
-
-
Kola, I.1
Landis, J.2
-
3
-
-
4944242884
-
A vision for the National Cancer Program in the United States
-
von Eschenbach A.C. A vision for the National Cancer Program in the United States. Nat. Rev. Cancer (2004) 4 820-828.
-
(2004)
Nat. Rev. Cancer
, vol.4
, pp. 820-828
-
-
von Eschenbach, A.C.1
-
4
-
-
79952366413
-
-
US Department of Health and Human Services. Food and Drug Administration Innovation or stagnation: challenges and opportunity on the critical path to new medical products. US Department of Health and Human Services
-
US Department of Health and Human Services. Food and Drug Administration Innovation or stagnation: challenges and opportunity on the critical path to new medical products. US Department of Health and Human Services. (2004)
-
(2004)
-
-
-
5
-
-
34047177929
-
Biomarker qualification pilot process at the US Food and Drug Administration
-
Goodsaid F., Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J. (2007) 9 E105-E108.
-
(2007)
AAPS J.
, vol.9
-
-
Goodsaid, F.1
Frueh, F.2
-
6
-
-
47349084016
-
Translational medicine: science or wishful thinking?
-
Wehling M. Translational medicine: science or wishful thinking? J Transl Med. (2008) 6 31.
-
(2008)
J Transl Med.
, vol.6
, pp. 31
-
-
Wehling, M.1
-
7
-
-
79952395015
-
-
US Department of Health and Human Services. Food and Drug Administration Guidance for industry, investigators, and reviewers: Exploratory IND studies. US Department of Health and Human Services. () ( ).
-
US Department of Health and Human Services. Food and Drug Administration Guidance for industry, investigators, and reviewers: Exploratory IND studies. US Department of Health and Human Services. (2006) ( ).
-
(2006)
-
-
-
8
-
-
33745406564
-
Slow start to Phase 0 as researchers debate value
-
Twombly R. Slow start to Phase 0 as researchers debate value. J. Natl Cancer Inst. (2006) 98 804-806.
-
(2006)
J. Natl Cancer Inst.
, vol.98
, pp. 804-806
-
-
Twombly, R.1
-
9
-
-
79952367573
-
NCI Phase 0 Working Group Inhibition of poly (ADP-ribose)polymerase (PARP) by ABT-888 in patients with advanced malignancies: results of a Phase 0 trial
-
3518.
-
Kummar S, Kinders R, Gutierrez M et al. NCI Phase 0 Working Group Inhibition of poly (ADP-ribose)polymerase (PARP) by ABT-888 in patients with advanced malignancies: results of a Phase 0 trial. (2007) J. Clin. Oncol. 25 3518.
-
(2007)
J. Clin. Oncol.
, vol.25
-
-
Kummar, S.1
Kinders, R.2
Gutierrez, M.3
-
10
-
-
33947380240
-
Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology
-
Ratnam K., Low J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. (2007) 13 1383-1388.
-
(2007)
Clin. Cancer Res.
, vol.13
, pp. 1383-1388
-
-
Ratnam, K.1
Low, J.A.2
-
11
-
-
67149128618
-
Phase 0 trials for anticancer drug development
-
No authors listed].
-
[No authors listed]. Phase 0 trials for anticancer drug development. Nat. Rev. Drug Discov. (2009) 8 442.
-
(2009)
Nat. Rev. Drug Discov.
, vol.8
, pp. 442
-
-
-
12
-
-
58849138367
-
Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
-
Takimoto C.H. Phase 0 clinical trials in oncology: a paradigm shift for early drug development? Cancer Chemother. Pharmacol. (2009) 63 703-709.
-
(2009)
Cancer Chemother. Pharmacol.
, vol.63
, pp. 703-709
-
-
Takimoto, C.H.1
-
13
-
-
33846677129
-
Comparison of treatment effects between animal experiments and clinical trials: systematic review
-
Perel P., Roberts I., Sena E. et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ (2007) 334 197.
-
(2007)
BMJ
, vol.334
, pp. 197
-
-
Perel, P.1
Roberts, I.2
Sena, E.3
-
14
-
-
1442311168
-
Where is the evidence that animal research benefits humans?
-
Pound P., Ebrahim S., Sandercock P., Bracken M.B., Roberts I. Where is the evidence that animal research benefits humans? BMJ (2004) 328 514-517.
-
(2004)
BMJ
, vol.328
, pp. 514-517
-
-
Pound, P.1
Ebrahim, S.2
Sandercock, P.3
Bracken, M.B.4
Roberts, I.5
-
15
-
-
33749615999
-
Translation of research evidence from animals to humans
-
Hackam D.G., Redelmeier D.A. Translation of research evidence from animals to humans. JAMA (2006) 296 1731-1732.
-
(2006)
JAMA
, vol.296
, pp. 1731-1732
-
-
Hackam, D.G.1
Redelmeier, D.A.2
-
16
-
-
27644468268
-
How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men
-
Corpet D.E., Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men Eur. J. Cancer (2005) 41 1911-1922.
-
(2005)
Eur. J. Cancer
, vol.41
, pp. 1911-1922
-
-
Corpet, D.E.1
Pierre, F.2
-
17
-
-
33846702343
-
Translating animal research into clinical benefit
-
Hackam D.G. Translating animal research into clinical benefit. BMJ (2007) 334 163-164.
-
(2007)
BMJ
, vol.334
, pp. 163-164
-
-
Hackam, D.G.1
-
18
-
-
0038616401
-
Emergency medicine animal research: does use of randomization and blinding affect the results?
-
Bebarta V., Luyten D., Heard K. Emergency medicine animal research: does use of randomization and blinding affect the results? Acad. Emerg. Med. (2003) 10 684-687.
-
(2003)
Acad. Emerg. Med.
, vol.10
, pp. 684-687
-
-
Bebarta, V.1
Luyten, D.2
Heard, K.3
-
19
-
-
0037160695
-
Does animal experimentation inform human health care? Observations from a systematic review of international animal experiments on fluid resuscitation
-
Roberts I., Kwan I., Evans P., Haig S. Does animal experimentation inform human health care? Observations from a systematic review of international animal experiments on fluid resuscitation BMJ (2002) 324 474-476.
-
(2002)
BMJ
, vol.324
, pp. 474-476
-
-
Roberts, I.1
Kwan, I.2
Evans, P.3
Haig, S.4
-
20
-
-
70350303591
-
Effects of NXY-059 in experimental stroke: an individual animal meta-analysis
-
Bath P.M.W., Gray L.J., Bath A.J.G. et al. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br. J. Pharmacol. (2009) 157, 1157-1171.
-
(2009)
Br. J. Pharmacol.
, vol.157
, pp. 1157-1171
-
-
Bath, P.M.W.1
Gray, L.J.2
Bath, A.J.G.3
-
21
-
-
34547795720
-
NXY-059 for the treatment of acute ischemic stroke
-
Shuaib A., Lees K.R., Lyden P. et al. NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. (2007) 357 562-571.
-
(2007)
N. Engl. J. Med.
, vol.357
, pp. 562-571
-
-
Shuaib, A.1
Lees, K.R.2
Lyden, P.3
-
22
-
-
54049103993
-
Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality
-
Macleod M.R., van der Worp H.B., Sena E.S., Howells D.W., Dirnagl U., Donnan G.A. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke (2008) 39 2824-2829.
-
(2008)
Stroke
, vol.39
, pp. 2824-2829
-
-
Macleod, M.R.1
van der Worp, H.B.2
Sena, E.S.3
Howells, D.W.4
Dirnagl, U.5
Donnan, G.A.6
-
23
-
-
0344065373
-
Recommendations for standards regarding preclinical neuroprotective and restorative drug development
-
Stroke Therapy Academic Industry Roundtable.
-
Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke (1999) 30 2752-2758.
-
(1999)
Stroke
, vol.30
, pp. 2752-2758
-
-
-
24
-
-
53249111808
-
The Translational Research Working Group developmental pathways: introduction and overview
-
Hawk E.T., Matrisian L.M., Nelson W.G. et al. The Translational Research Working Group developmental pathways: introduction and overview. Clin. Cancer Res. (2008) 14, 5664-5671.
-
(2008)
Clin. Cancer Res
, vol.14
, pp. 5664-5671
-
-
Hawk, E.T.1
Matrisian, L.M.2
Nelson, W.G.3
-
25
-
-
67650069258
-
Assessing the translatability of drug projects: what needs to be scored to predict success?
-
Wehling M. Assessing the translatability of drug projects: what needs to be scored to predict success? Nat. Rev. Drug Discov. (2009) 8 541-546.
-
(2009)
Nat. Rev. Drug Discov.
, vol.8
, pp. 541-546
-
-
Wehling, M.1
-
26
-
-
33645388385
-
Translational medicine: can it really facilitate the transition of research "from bench to bedside"?
-
Wehling M. Translational medicine: can it really facilitate the transition of research "from bench to bedside"? Eur. J. Clin. Pharmacol. (2006) 62 91-95.
-
(2006)
Eur. J. Clin. Pharmacol.
, vol.62
, pp. 91-95
-
-
Wehling, M.1
|